-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
September 08, 2020 // -- Boehringer Ingelheim and Pharmaxis recently jointly announced the termination of the development of BI1467335 for the treatment of moderate to non-proliferative diabetic retinal lesions (NPDR).
the end of last year, the two sides announced the end of the development of BI1467335 treatment of non-alcoholic fatty hepatitis (NASH).
BI1467335, an anti-inflammatory copper-containing oxidase 3 (AOC3) inhibitor, was acquired from Pharmaxis in 2015.
now, Grigg Ingham will terminate the agreement.
in a Phase IIa trial for patients with moderate to severe NPDR, BI1467335 reached the primary endpoint of eye safety and was well treated.
Bronger Ingham decided not to further develop BI1467335 for the treatment of NPDR because the compound lacked clear signals of efficacy and there was a risk of dose-dependent drug interactions in another Phase I study for NPDR patients.
BI1467335 Chemical Structure (Photo: probechem.cn) In December last year, a 12-week Phase IIa trial with NASH clinical evidence showed that BI1467335 was well- resistant and did not have serious adverse events associated with treatment, according to a statement from Blinger Ingham and Pharmaxis.
compared to placebos, BI1467335 achieved the intended goal of inhibiting the activity of copper-containing copperamine oxidase 3 (AOC3) in plasma and clinically related changes in NASH biomarkers.
, however, after evaluating another Phase I study that had been completed, Grigg Ingham decided not to further develop BI1467335 in NASH adaptation because of the risk of drug interactions in NASH patients. gary Phillips, chief executive of
Pharmaxis, said: "We understand Grigg Ingham's decision to stop the development of BI1467335 in NPDR due to the risk of dose-dependent drug interactions.
, according to recent publications, AOC3 remains an important clinical target.
We will review the data collected in more detail to assess potential opportunities for other adaptations, which already have preclinically supported data and the risk of drug interactions is of little concern.
() Original source: Boehringer Ingelheim Discontinues Development of BI 1467335 for Diabetic Retinopathy.
